School of Medicine

Wayne State University School of Medicine

Profile View

Edwin B. George II
Assistant Professor of Neurology; Director, Movement Disorders Center
313-745-4275 WSU; 313 576 3529 VAMC

Dr. George joined the Wayne State University School of Medicine faculty in 1996, and he is Director of the Wayne State University Movement Disorders Center and also Director of the Movement Disorders Clinic at the John D. Dingell VA Medical Center. He is chairman of the Professional Advisory Board of the Michigan Parkinson's Foundation, and serves on the Movement Disorders Strategic Planning Committee of the American Academy of Neurology. He is Co-Director of the Neuropathophysiology curriculum for the Wayne State University School of Medicine.

Dr. George’s research interests include clinical management of Parkinson’s disease, tremor and dystonia, and he has been active in clinical trials of new medications for Parkinson’s disease and dystonia. He is also involved in research on measuring the impact of neurological disease on patient function. Dr. George’s laboratory research has focused on neuronal reaction to injury and neural regeneration. Dr. George has a Ph.D. in pharmacology, as well as an M.D., from Case Western Reserve University, and was a Grass Fellow in Neurophysiology at the Marine Biological Laboratory in Woods Hole, MA. He has lectured and written extensively on movement disorders, and has served as a consultant to U.S. and international pharmaceutical firms.

Amherst College, B.A., 1980
Case Western Reserve University, Ph.D. (Pharmacology), 1985

Case Western Reserve University, M.D., 1987

The Johns Hopkins Hospital, 1988-1991
Grass Fellowship in Neurophysiology, Marine Biological Laboratory, Woods Hole, Massachusetts, 1986
Prior Appointments

Instructor of Neurology, Johns Hopkins University, Baltimore, MD, 1991-1993

Assistant Professor of Neurology, Johns Hopkins University, Baltimore, MD, 1993-1996


Parkinson’s disease and other movement disorders, botulinum toxin therapy, neuropathies and peripheral nerve diseases, spinal cord injury and disease, neurotoxicology


George, E.B., Schneider, B.F., Lasek, R.J., and Katz, M.J. 1988. Axonal Shortening and the Mechanisms of Axonal Motility. Cell Motility 9:48-59
Glass, J.D., Brushart, T.M., George, E.B., Griffin, J.W. 1993. Prolonged Survival of Transected Nerve Fibers in C57BL/Ola Mice is an Intrinsic Characteristic of the Axon. J. Neurocytol. 22:311-321
George E.B. 1993. Biological Toxins, in Current Therapy in Neurologic Disease-4, R.T. Johnson, ed. Philadelphia: B.C. Decker, Inc.
Lyons, W.E., George, E.B., Dawson, T.M., Steiner, J.P., Snyder, S.H. 1994. Immunosuppressant FK506 Promotes Neurite Outgrowth in Cultures of PC-12 Cells and Sensory Ganglia. Proc. Nat. Acad. Sci. 91:3191 3195
Kuncl, R.W., George, E.B. 1993. Toxic Neuropathies and Myopathies. Curr. Opinion in Neurol. Neurosurg. 6:695-704
Pestronk A, Choksi R, Bieser K, Goldstein JM, Adler CH, Caselli RJ, George EB. 1994. Treatable Gait Disorder and Polyneuropathy Associated with High Titer Serum IGM Binding to Antigens That Copurify with Myelin Associated Glycoprotein. Muscle & Nerve 11:1293 1300
Griffin, J.W., George, E.B., Chaudhry, V. 1996.  Wallerian Degeneration in Peripheral Nerve Disease, in Baillière's Clinical Neurology, Vol. 5, No. 1, Peripheral Neuropathies: Part II, H. P. Hartung, ed. Philadelphia: W.B. Saunders Co.
George, E.B., Glass, J.D., Griffin, J.W. 1995. Axotomy-Induced Axonal Degeneration Is Mediated by Calcium Influx Through Ion-Specific Channels. J. Neurosci. 15:6445 6452
Johnson, K., George, E.B. 1997. The Rubber Meets the Road: Integrating the Unified Medical Language System Knowledge Source Server into the Computer-based Patient Record. J. Am. Med. Inform. Assoc. Symposium Suppl.
Tsao, J.W., George, E.B., Griffin, J.W. 1999. Temperature Modulation Reveals Three Distinct Stages of Wallerian Degeneration.   J. Neurosci.  19:4718-4726
Benjamins, J.A., Nedelkoska, L., George, E.B. 2003. Protection of Mature Oligodendrocytes by Inhibitors of Caspases and Calpains. Neurochem. Res. 28:143–152
Elble, RJ for the Tremor Research Group and Conference Attendees. Report From a U.S. Conference on Essential Tremor. Movement Disorders, 2006 21:2052–2061
George, E.B. 2003. Neurology, in USMLE Step 3 Recall, M.W. Ryan, ed. Philadelphia: Lippincott, Williams and Wilkens
Hohfeld R, Kappos L, Arnason B, Bates D, Bruck W, Clanet M, Dirnagl U, Ebers G,Fieschi C, Fredrikson S, Gass A, George E, Gold R, Goodin D, Hakim A, Hartung H-P, Iadecola C, Lubetzki C, Karussis D, Kerschensteiner M, Milonas I, Montalbam X, Rice G, Zamvil S. Neuroprotection in Multiple Sclerosis, Proceedings of the MS Forum Modern Management Workshop March 2004
Borsody M, George E. 2006. Movement Disorders, in Comprehensive Board Review in Neurology, Borsody M, ed. New York: Thieme Medical Publishers
Soliman S, Haque S, George E. Stalking and Huntington’s Disease: A Neurobiological Link? Journal of Forensic Sciences, 2007 52:1202-1204
C.B. Colen, A. Ketko, E.B. George, G.VanStavern. Periodic Alternating Nystagmus with Periodic Alternating Skew Deviation in Spinocerebellar Ataxia Type 6, Journal of Neuro-Ophthalmology, in press

Awards & Honors
  • Listed in Best Doctors in America and Best Doctors in Michigan


  • Received the 2010 Successful REcruitment Award for the highest number of total matches of USA medical schools foe students matching in Neurology


  • Elected chair of the Board of Directors, Michigan Parkinsons Disease Foundation in 2010


  • John Woodruff Simpson Fellowship for Study in Biophysics and Medicine


  • Noether Memorial Fund Award for Excellence in Therapeutics


  • Clinician Scientist Award, Johns Hopkins School of Medicine


  • Wayne State University College Teaching Award


Other Information

New research funding awarded in 2011

“Flex: An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin (incobotulinumtoxin A) [Short Flex vs Long Flex] in Subjects with Cervical Dystonia with< 10 Weeks of Benefit from OnabotulinumtoxinA Treatment.” Sponsor: Merz Pharmaceuticals. Edwin George, PI, Mary Shaya, co-PI.

Merz Pharmaceuticals LLC, CD FLEX: An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex vs. Long Flex] in Subjects with Cervical Dystonia with < 10 Weeks of Benefit from OnabotulinumtoxinA Treatment. Q4,2011-Q3,2016, local PI: E.B. George

New research funding awarded in 2010

 Effect of rasagiline (AzilectÒ) on Tissue Injury in Patients with Parkinson’s Disease: An Exploratory non-conventional multi-modal MRI study.” Sponsor: Teva Neuroscience. Omar Khan, PI, Edwin George, co-PI.